Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity

Genes and Development

Volumn 25, Issue 20, 2011, Pages 2125-2136

  Chien, Yuchen ^a   Scuoppo, Claudio ^a   Wang, Xiaowo ^b   Fang, Xueping ^c   Balgley, Brian ^d   Bolden, Jessica E ^a   Premsrirut, Prem ^a   Luo, Weijun ^a   Chicas, Agustin ^a   Lee, Cheng S ^c   Kogan, Scott C ^e   Lowe, Scott W ^a,f,g  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b TSINGHUA UNIVERSITY   (China)

^c UNIVERSITY OF MARYLAND   (United States)

^d Calibrant   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemoresistance; Lymphoma; NF B; SASP; Senescence

Indexed keywords

CYCLOPHOSPHAMIDE; DOXYCYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA; SYNAPTOTAGMIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOSENSITIVITY; CHROMATIN; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SENESCENCE; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE;

ANIMALS; CELL AGING; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MICE; PHENOTYPE; PROTEIN SYNTHESIS INHIBITORS; RNA, SMALL INTERFERING; TETRACYCLINE; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054789761     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.17276711     Document Type: Article

References (58)

1. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, et al. 2008. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133: 1006-1018.
2. Basseres DS, Baldwin AS. 2006. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830.
3. Batsi C, Markopoulou S, Vartholomatos G, Georgiou I, Kanavaros P, Gorgoulis VG, Marcu KB, Kolettas E. 2009. Chronic NF-κB activation delays RasV12-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. Mech Ageing Dev 130: 409-419.
4. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J. 2003. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22: 4212-4222.
5. Campisi J. 2005. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120: 513-522.
6. Campisi J, Fagagna F. 2007. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
7. Chen HZ, Tsai SY, Leone G. 2009. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9: 785-797.
8. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe SW. 2010. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17: 376-387.
9. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, et al. 2009. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459: 717-721.
10. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. 2008. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
11. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, et al. 2003. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421: 639-643.
12. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. 2010. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88-92.
13. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, et al. 2010. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468: 572-575.
14. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027.
15. Freund A, Orjalo AV, Desprez PY, Campisi J. 2010. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 16: 238-246.
16. Hardy K, Mansfield L, Mackay A, Benvenuti S, Ismail S, Arora P, O'Hare MJ, Jat PS. 2005. Transcriptional networks and cellular senescence in human mammary fibroblasts. Mol Biol Cell 16: 943-953.
17. Hayden MS, West AP, Ghosh S. 2006. NF-κB and the immune response. Oncogene 25: 6758-6780.
18. Hoffmann A, Baltimore D. 2006. Circuitry of nuclear factor κB signaling. Immunol Rev 210: 171-186.
19. Jing H, Kase J, Dörr JR, Milanovic M, Lenze D, Grau M, Beuster G, Ji S, Reimann M, Lenz P, et al. 2011. Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (this issue). doi: 10.1101/gad.17620611.
20. Karin M. 2006. Nuclear factor-κB in cancer development and progression. Nature 441: 431-436.
21. Kortlever RM, Higgins PJ, Bernards R. 2006. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877-884.
22. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. 2008. Senescence of activated stellate cells limits liver fibrosis. Cell 134: 657-667.
23. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. 2001. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci 98: 12072-12077.
24. Kuilman T, Peeper DS. 2009. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9: 81-94.
25. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. 2008. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133: 1019-1031.
26. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. 2010. The essence of senescence. Genes Dev 24: 2463-2479.
27. Lin Y, Benchimol S. 1997. p53-mediated cell cycle arrest and apoptosis. Leukemia (Suppl 3) 11: 324-326.
28. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12: 3008-3019.
29. Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T, Pellicer A. 2000. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol 20: 2915-2925.
30. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, Roberts AW. 2008. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci 105: 17961-17966.
31. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. 2009. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462: 104-107.
32. Mooi WJ, Peeper DS. 2006. Oncogene-induced cell senescence- halting on the road to cancer. N Engl J Med 355: 1037-1046.
33. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716.
34. Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP, Lowe SW. 2006. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126: 503-514.
35. Nogai H, Dorken B, Lenz G. 2011. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 29: 1803-1811.
36. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E. 2001. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067-1070.
37. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, et al. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210.
38. Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, et al. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145: 145-158.
39. Rodier F, Coppé JP, Patil CK, Hoeijmakers WA, Muñoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. 2009. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11: 973-979.
40. Roninson IB. 2003. Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715.
41. Rovillain E, Mansfield L, Caetano C, Alvarez-Fernandez M, Caballero OL, Medema RH, Hummerich H, Jat PS. 2011. Activation of nuclear factor-κB signalling promotes cellular senescence. Oncogene 30: 2356-2366.
42. Rowland BD, Bernards R, Peeper DS. 2005. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 7: 1074-1082.
43. Ryan KM, Ernst MK, Rice NR, Vousden KH. 2000. Role of NFkB in p53-mediated programmed cell death. Nature 404: 892-897.
44. Scaffidi P, Misteli T, Bianchi ME. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.
45. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-2677.
46. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346.
47. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
48. Shelton DN, Chang E, Whittier PS, Choi D, Funk WD. 1999. Microarray analysis of replicative senescence. Curr Biol 9: 939-945.
49. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. 2002. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62: 1876-1883.
50. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. 2008. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374.
51. Wan F, Lenardo MJ. 2009. Specification of DNA binding activity of NF-κB proteins. Cold Spring Harb Perspect Biol 1: a000067. doi: 10.1101/cshperspect.a000067.
52. Wang J, Jacob NK, Ladner KJ, Beg A, Perko JD, Tanner SM, Liyanarachchi S, Fishel R, Guttridge DC. 2009. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep 10: 1272-1278.
53. Whitlock CA, Witte ON. 1987. Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol 150: 275-286.
54. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611.
55. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
56. Zhang R, Chen W, Adams PD. 2007. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 27: 2343-2358.
57. Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12: 2997-3007.
58. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. 2004. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18: 1272-1282.